Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TYK-01054 in Advanced Solid Tumors
NCT07282873Phase 2Not yet recruiting
- Sponsor
- TYK Medicines
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TY-1054 in solid tumor, malignant mesothelioma (MM), small cell lung cancer (SCLC), head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC), sponsored by TYK Medicines. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
TY-1054
03
Conditions
solid tumormalignant mesothelioma (MM)small cell lung cancer (SCLC)head and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07282873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07282873.